Lutetium (177Lu) for Prostate Cancer Long-Term Safety
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Recruiting
Phase 4
Interventional Study
Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 100
- Sex
- Male
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 700 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Who this trial is looking for
This trial is looking for adult men who have received a treatment called lutetium (177Lu) vipivotide tetraxetan for prostate cancer in previous clinical trials. Participants will help researchers understand the long-term safety and risks of this treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I have given my consent to participate in the study.
- I have received at least one dose of lutetium (177Lu) vipivotide tetraxetan in a previous clinical trial for prostate cancer.
You may not be able to join if
- I am unable to complete the required examinations for the study.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults wit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Signed informed consent must be obtained prior to participation in the study
* Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them …
Contacts